Pulmonary resection for metastatic malignant fibrous histiocytoma: An analysis of prognostic factors

Rakesh M. Suri, Claude Deschamps, Stephen D. Cassivi, Francis C. Nichols, Mark S. Allen, Cathy D. Schleck, Peter C. Pairolero

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Factors affecting recurrence and survival after pulmonary resection for metastatic malignant fibrous histiocytoma (MFH) are not well known. Methods. Records of patients undergoing pulmonary metastasectomy for MFH between January 1976 and January 2000 were analyzed. Results. There were 103 patients (46 men and 57 women). Median age was 60 years (range, 20 to 86). Malignant fibrous histiocytoma metastasis was solitary in 29 patients (28%), multiple/unilateral in 33 (32%), and multiple/bilateral in 41 (40%). Median time interval from primary tumor resection to metastasectomy was 11 months (range, 0 to 86). Wedge resection was carried out in 87 patients (84%), segmentectomy in 3 (3%), lobectomy in 3 (3%), pneumonectomy in 2 (2%), and a combination of resections in 8 (8%). Resection was complete in 93 patients (90%). Complications occurred in 11 patients (11%) and included prolonged air leak in 7, and pneumonia, empyema, atelectasis, and sepsis in 1 each. One patient died (operative mortality, 1%). Follow-up ranged from 2 weeks to 153 months (median, 18 months). Five-year survival was 21% (95% confidence interval, 14% to 31%). In the 103 patients, incomplete resection (p < 0.0001) was associated with decreased survival. Among the 93 patients with complete resection, factors associated with decreased survival included the presence of extrapulmonary disease at time of metastasectomy (p = 0.01), more than two nodules resected (p = 0.001), and adjuvant therapy after metastasectomy (p = 0.0007). Conclusions. Pulmonary resection of metastatic MFH is safe. Improved survival was associated with the absence of extrapulmonary disease at time of metastasectomy, with fewer than three pulmonary nodules resected, and with a complete resection.

Original languageEnglish (US)
Pages (from-to)1847-1852
Number of pages6
JournalAnnals of Thoracic Surgery
Volume80
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Malignant Fibrous Histiocytoma
Metastasectomy
Lung
Survival
Empyema
Pulmonary Atelectasis
Segmental Mastectomy
Pneumonectomy
Sepsis
Pneumonia
Air
Confidence Intervals
Neoplasm Metastasis
Recurrence
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Suri, R. M., Deschamps, C., Cassivi, S. D., Nichols, F. C., Allen, M. S., Schleck, C. D., & Pairolero, P. C. (2005). Pulmonary resection for metastatic malignant fibrous histiocytoma: An analysis of prognostic factors. Annals of Thoracic Surgery, 80(5), 1847-1852. https://doi.org/10.1016/j.athoracsur.2005.05.004

Pulmonary resection for metastatic malignant fibrous histiocytoma : An analysis of prognostic factors. / Suri, Rakesh M.; Deschamps, Claude; Cassivi, Stephen D.; Nichols, Francis C.; Allen, Mark S.; Schleck, Cathy D.; Pairolero, Peter C.

In: Annals of Thoracic Surgery, Vol. 80, No. 5, 11.2005, p. 1847-1852.

Research output: Contribution to journalArticle

Suri, RM, Deschamps, C, Cassivi, SD, Nichols, FC, Allen, MS, Schleck, CD & Pairolero, PC 2005, 'Pulmonary resection for metastatic malignant fibrous histiocytoma: An analysis of prognostic factors', Annals of Thoracic Surgery, vol. 80, no. 5, pp. 1847-1852. https://doi.org/10.1016/j.athoracsur.2005.05.004
Suri, Rakesh M. ; Deschamps, Claude ; Cassivi, Stephen D. ; Nichols, Francis C. ; Allen, Mark S. ; Schleck, Cathy D. ; Pairolero, Peter C. / Pulmonary resection for metastatic malignant fibrous histiocytoma : An analysis of prognostic factors. In: Annals of Thoracic Surgery. 2005 ; Vol. 80, No. 5. pp. 1847-1852.
@article{dd368a1a0b8e4ec3be80e31ccb27bebd,
title = "Pulmonary resection for metastatic malignant fibrous histiocytoma: An analysis of prognostic factors",
abstract = "Background. Factors affecting recurrence and survival after pulmonary resection for metastatic malignant fibrous histiocytoma (MFH) are not well known. Methods. Records of patients undergoing pulmonary metastasectomy for MFH between January 1976 and January 2000 were analyzed. Results. There were 103 patients (46 men and 57 women). Median age was 60 years (range, 20 to 86). Malignant fibrous histiocytoma metastasis was solitary in 29 patients (28{\%}), multiple/unilateral in 33 (32{\%}), and multiple/bilateral in 41 (40{\%}). Median time interval from primary tumor resection to metastasectomy was 11 months (range, 0 to 86). Wedge resection was carried out in 87 patients (84{\%}), segmentectomy in 3 (3{\%}), lobectomy in 3 (3{\%}), pneumonectomy in 2 (2{\%}), and a combination of resections in 8 (8{\%}). Resection was complete in 93 patients (90{\%}). Complications occurred in 11 patients (11{\%}) and included prolonged air leak in 7, and pneumonia, empyema, atelectasis, and sepsis in 1 each. One patient died (operative mortality, 1{\%}). Follow-up ranged from 2 weeks to 153 months (median, 18 months). Five-year survival was 21{\%} (95{\%} confidence interval, 14{\%} to 31{\%}). In the 103 patients, incomplete resection (p < 0.0001) was associated with decreased survival. Among the 93 patients with complete resection, factors associated with decreased survival included the presence of extrapulmonary disease at time of metastasectomy (p = 0.01), more than two nodules resected (p = 0.001), and adjuvant therapy after metastasectomy (p = 0.0007). Conclusions. Pulmonary resection of metastatic MFH is safe. Improved survival was associated with the absence of extrapulmonary disease at time of metastasectomy, with fewer than three pulmonary nodules resected, and with a complete resection.",
author = "Suri, {Rakesh M.} and Claude Deschamps and Cassivi, {Stephen D.} and Nichols, {Francis C.} and Allen, {Mark S.} and Schleck, {Cathy D.} and Pairolero, {Peter C.}",
year = "2005",
month = "11",
doi = "10.1016/j.athoracsur.2005.05.004",
language = "English (US)",
volume = "80",
pages = "1847--1852",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Pulmonary resection for metastatic malignant fibrous histiocytoma

T2 - An analysis of prognostic factors

AU - Suri, Rakesh M.

AU - Deschamps, Claude

AU - Cassivi, Stephen D.

AU - Nichols, Francis C.

AU - Allen, Mark S.

AU - Schleck, Cathy D.

AU - Pairolero, Peter C.

PY - 2005/11

Y1 - 2005/11

N2 - Background. Factors affecting recurrence and survival after pulmonary resection for metastatic malignant fibrous histiocytoma (MFH) are not well known. Methods. Records of patients undergoing pulmonary metastasectomy for MFH between January 1976 and January 2000 were analyzed. Results. There were 103 patients (46 men and 57 women). Median age was 60 years (range, 20 to 86). Malignant fibrous histiocytoma metastasis was solitary in 29 patients (28%), multiple/unilateral in 33 (32%), and multiple/bilateral in 41 (40%). Median time interval from primary tumor resection to metastasectomy was 11 months (range, 0 to 86). Wedge resection was carried out in 87 patients (84%), segmentectomy in 3 (3%), lobectomy in 3 (3%), pneumonectomy in 2 (2%), and a combination of resections in 8 (8%). Resection was complete in 93 patients (90%). Complications occurred in 11 patients (11%) and included prolonged air leak in 7, and pneumonia, empyema, atelectasis, and sepsis in 1 each. One patient died (operative mortality, 1%). Follow-up ranged from 2 weeks to 153 months (median, 18 months). Five-year survival was 21% (95% confidence interval, 14% to 31%). In the 103 patients, incomplete resection (p < 0.0001) was associated with decreased survival. Among the 93 patients with complete resection, factors associated with decreased survival included the presence of extrapulmonary disease at time of metastasectomy (p = 0.01), more than two nodules resected (p = 0.001), and adjuvant therapy after metastasectomy (p = 0.0007). Conclusions. Pulmonary resection of metastatic MFH is safe. Improved survival was associated with the absence of extrapulmonary disease at time of metastasectomy, with fewer than three pulmonary nodules resected, and with a complete resection.

AB - Background. Factors affecting recurrence and survival after pulmonary resection for metastatic malignant fibrous histiocytoma (MFH) are not well known. Methods. Records of patients undergoing pulmonary metastasectomy for MFH between January 1976 and January 2000 were analyzed. Results. There were 103 patients (46 men and 57 women). Median age was 60 years (range, 20 to 86). Malignant fibrous histiocytoma metastasis was solitary in 29 patients (28%), multiple/unilateral in 33 (32%), and multiple/bilateral in 41 (40%). Median time interval from primary tumor resection to metastasectomy was 11 months (range, 0 to 86). Wedge resection was carried out in 87 patients (84%), segmentectomy in 3 (3%), lobectomy in 3 (3%), pneumonectomy in 2 (2%), and a combination of resections in 8 (8%). Resection was complete in 93 patients (90%). Complications occurred in 11 patients (11%) and included prolonged air leak in 7, and pneumonia, empyema, atelectasis, and sepsis in 1 each. One patient died (operative mortality, 1%). Follow-up ranged from 2 weeks to 153 months (median, 18 months). Five-year survival was 21% (95% confidence interval, 14% to 31%). In the 103 patients, incomplete resection (p < 0.0001) was associated with decreased survival. Among the 93 patients with complete resection, factors associated with decreased survival included the presence of extrapulmonary disease at time of metastasectomy (p = 0.01), more than two nodules resected (p = 0.001), and adjuvant therapy after metastasectomy (p = 0.0007). Conclusions. Pulmonary resection of metastatic MFH is safe. Improved survival was associated with the absence of extrapulmonary disease at time of metastasectomy, with fewer than three pulmonary nodules resected, and with a complete resection.

UR - http://www.scopus.com/inward/record.url?scp=26844527319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844527319&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2005.05.004

DO - 10.1016/j.athoracsur.2005.05.004

M3 - Article

C2 - 16242467

AN - SCOPUS:26844527319

VL - 80

SP - 1847

EP - 1852

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -